Endocrinology Video Recap—November 18, 2025

LucidQuest

17 minutes ago

This biweekly endocrinology roundup covers new clinical guidelines, major health-service updates, advances in therapeutic innovation, key clinical trial findings, regulatory milestones, and policy insights shaping patient care.

🎯 Watch Our Video Summary Capturing Endocrinology News from the Last Two Weeks

Dive deeper

🗓️ Explore weekly details and sources

Week 3–10 October 2025
Week 11–17 November 2025

📚 See the full Endocrinology archive on our research hub pag

Transcript

Welcome to the latest edition of Endocrinology Updates, covering the latest breakthroughs. Brought to you by LucidQuest, this update highlights:

Diabetes UK highlighted a new NHS pathway for children with early-stage type 1. The pathway covers confirming autoantibodies, setting a monitoring cadence, deciding when to start insulin, and how to handle single-autoantibody presentations. It also points families and clinicians to evaluation materials. The intent is practical, intercept risk sooner, support families with clear steps, and align services for future screening programs.

Hamad Medical Corporation expanded bone health services. The package includes more specialist clinics, advanced diagnostics, and a fracture liaison service that coordinates post-fracture care. The focus is earlier risk stratification, appropriate initiation of approved osteoporosis therapies, and structured follow-up to cut secondary fractures.

Avant Technologies and SGAustria announced a joint venture and license agreement aimed at encapsulated, stem-cell-derived insulin-producing cells. The plan includes a U.S. vehicle, Insulinova, Inc., with funding directed at early clinical work. The goal, address type 1 and some insulin-dependent type 2 with a cell-based modality that sits alongside current drug and device options.

Public Health Wales research informed new support for people living with type 2 diabetes. Planned features include a digital support hub, clinician packs, updates to the NHS Wales app, and expanded peer networks. The aim is day-to-day self management that is easier to start, simpler to sustain, and more connected to clinical teams.

At the AHA Scientific Sessions, with a Jama paper, the Permet trial reported that metformin did not improve the 6 minute walk distance in peripheral artery disease without diabetes at 6 months versus placebo. Secondary outcomes were also neutral, and safety was similar. For prescribers and payers this calibrates expectations and may shift choices toward therapies with demonstrated functional benefit in this population.

EMA advisers at CHMP issued a positive opinion for teplizumab to delay progression to stage 3 type 1 diabetes. The recommendation is based on placebo controlled data showing longer time to onset. A European Commission decision is next. If approved, it introduces competition in prevention stage therapy, with likely implications for pricing and formulary access.

The FDA signaled plans to remove black box warnings on many menopause and perimenopause hormone therapy products, both estrogen containing and combination, citing updated risk benefit understanding and availability of non hormonal options. The change is intended to reduce undertreatment while keeping safety guidance aligned with current evidence.

The European Society of Endocrinology revised its adult hypoparathyroidism guideline. Chronic postsurgical disease is now defined at 12 months. The document outlines an algorithm for when to consider PTH therapy after conventional management, which supports more consistent escalation decisions.

Stay ahead in endocrinology research! Like, share, and subscribe for weekly updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time.

🗓️ Explore weekly details and sources

Week 3–10 October 2025
Week 11–17 November 2025

📚 See the full Endocrinology archive on our research hub page.

Why it matters

Early interception: UK pathway operationalizes care for children with early-stage type 1, aligning systems for future screening and prevention.
Service access: Qatar and Wales initiatives target earlier detection and continuous support, which can shift outcomes.
Modalities: Cell-based JV underscores diversification beyond drugs for diabetes management.
Evidence calibration: PERMET and HRT labeling moves reflect evolving benefit–risk assessments.
Standards: ESE guidance clarifies timing and escalation paths in hypoparathyroidism.

FAQ

What does the UK early-stage type 1 pathway cover for children?

It outlines confirming autoantibodies, monitoring, when to start insulin, handling single-autoantibody cases, and evaluation materials for families and clinicians [1].

How is HMC changing osteoporosis care in Qatar?

By expanding specialist clinics, deploying advanced diagnostics, and coordinating post-fracture care through a liaison clinic to reduce future fractures [2].

What is the Avant–SGAustria diabetes JV aiming to deliver?

An encapsulated stem-cell therapy generating insulin-producing cells for type 1 and some insulin-dependent type 2, with a U.S. trial vehicle, Insulinova, Inc. [3].

What new support will NHS Wales offer for type 2 diabetes?

An enhanced digital hub, clinician support packs, NHS app updates, and expanded peer networks to aid day-to-day self-management [4].

What did PERMET show about metformin in PAD without diabetes?

Metformin did not improve 6-minute walk distance or secondary outcomes vs placebo at 6 months in a PAD cohort without diabetes [5].

What did EMA advisers decide on teplizumab?

CHMP recommended approval to delay progression to stage 3 type 1 diabetes, moving to a European Commission decision next [6].

What HRT label change did the FDA signal?

Per the Commissioner’s interview, many menopause and perimenopause HRT products will have black-box warnings removed to reflect current evidence [7].

What is new in ESE’s hypoparathyroidism guideline?

Chronic postsurgical disease is now defined at 12 months, with clearer steps for when to consider PTH replacement after conventional therapy [8].

Entities / Keywords

Early-stage type 1 pathway; Autoantibodies; Diabetes UK; G6PD deficiency; HbA1c; Type 2 diabetes support; HMC Qatar; Osteoporosis; Fracture liaison; Avant Technologies; SGAustria; Insulinova; Encapsulation; Teplizumab, Teizeild; Sanofi; CHMP; PERMET; Metformin; PAD; FDA; Menopause HRT; ESE; Hypoparathyroidism; PTH therapy.